ACAD Stock Summary

• For ACAD, its debt to operating expenses ratio is greater than that reported by merely 8.69% of US equities we're observing.
• ACAD's price/sales ratio is 23.28; that's higher than the P/S ratio of 94.63% of US stocks.
• Equity multiplier, or assets relative to shareholders' equity, comes in at 1.15 for Acadia Pharmaceuticals Inc; that's greater than it is for only 9.52% of US stocks.
• If you're looking for stocks that are quantitatively similar to Acadia Pharmaceuticals Inc, a group of peers worth examining would be NSTG, PACB, IVAC, FIT, and MANH.
• Visit ACAD's SEC page to see the company's official filings. To visit the company's web site, go to www.acadia-pharm.com.